Recently, aberrant expression of IGF pathway members was described in osteosarcomas and OSI-906, a dual inhibitor of the IGF1R and the IR, inhibited proliferation in 3 out of 4 osteosarcoma cell lines with IC50 values within the therapeutic range [24]. The gene discussed is IGF1R; the disease is osteosarcoma.